Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease is a progressive and debilitating condition. Early and effective treatment using a treat-to-target approach is key to improving patient outcomes. Therefore, proactive monitoring is essential to ensure that treatment strategies are working and targets are being met. In this review we discuss the current monitoring tools available to us and how they can be used. We also discuss the importance of monitoring during key phases of the disease and propose an optimum treat-to-target monitoring strategy for Crohn's disease and ulcerative colitis. Regarding the advent of new technology, we discuss how this may improve our monitoring capabilities and how we envisage future monitoring strategies of inflammatory bowel diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-performance medicine: the convergence of human and artificial intelligence
Topol, E. J. (2019) · Nature Medicine · doi:10.1038/s41591-018-0300-7 · Cited by 10,450
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases
Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., Ajami, N. J., Bonham, K. S., Brislawn, C. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1237-9 · Cited by 3,143
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
Cellier, C., Sahmoud, T., Froguel, E., Adenis, A., Belaiche, J., Bretagne, J. F., Florent, C., Bouvry, M., Mary, J. Y., & Modigliani, R. (1994) · Gut · doi:10.1136/gut.35.2.231 · Cited by 430
Stidham, R. W., Liu, W., Bishu, S., Rice, M. D., Higgins, P. D. R., Zhu, J., Nallamothu, B. K., & Waljee, A. K. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.3963 · Cited by 285
Barua, I., Vinsard, D. G., Jodal, H. C., Løberg, M., Kalager, M., Holme, Ø., Misawa, M., Bretthauer, M., & Mori, Y. (2021) · Endoscopy · doi:10.1055/a-1201-7165 · Cited by 271
Big data in IBD: big progress for clinical practice
Seyed Tabib, N. S., Madgwick, M., Sudhakar, P., Verstockt, B., Korcsmaros, T., & Vermeire, S. (2020) · Gut · doi:10.1136/gutjnl-2019-320065 · Cited by 223
IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
Jones, G.-R., Lyons, M., Plevris, N., Jenkinson, P. W., Bisset, C., Burgess, C., Din, S., Fulforth, J., Henderson, P., Ho, G.-T., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318936 · Cited by 206
Self-citationNovel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis
Galipeau, H. J., Caminero, A., Turpin, W., Bermudez-Brito, M., Santiago, A., Libertucci, J., Constante, M., Raygoza Garay, J. A., Rueda, G., Armstrong, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.004 · Cited by 190
Gracie, D. J., Williams, C. J. M., Sood, R., Mumtaz, S., Bholah, H. M., Hamlin, J. P., & Ford, A. C. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.59 · Cited by 173
Fully automated endoscopic disease activity assessment in ulcerative colitis
Yao, H., Najarian, K., Gryak, J., Bishu, S., Rice, M. D., Waljee, A. K., Wilkins, H. J., & Stidham, R. W. (2021) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.08.011 · Cited by 118
Sehgal, P., Ungaro, R. C., Foltz, C., Iacoviello, B., Dubinsky, M. C., & Keefer, L. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa196 · Cited by 82
Ludvigsson, J. F., Olén, O., Larsson, H., Halfvarson, J., Almqvist, C., Lichtenstein, P., & Butwicka, A. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab039 · Cited by 76
Cited by
Dolinger, M., Torres, J., & Vermeire, S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02586-2 · Cited by 580
Breaking through the therapeutic ceiling: what will it take?
Raine, T., & Danese, S. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.09.078 · Cited by 160
When AI speaks like a specialist: ChatGPT-4 in the management of inflammatory bowel disease
De Cristofaro, E., Zorzi, F., Abreu, M., Colella, A., Blanco, G. D. V., Fiorino, G., Lolli, E., Noor, N., Lopetuso, L. R., Pioche, M., et al. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1678320 · Cited by 1
“Inflammatory bowel diseases (IBD) are chronic and often disabling conditions that require continuous patient engagement, education, and support (Monteleone et al., 2023; Plevris and Lees, 2022).”
Metadata
- Authors
- Plevris, N., & Lees, C. W.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 162
- Issue
- 5
- Pages
- 1456-1475.e1
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W4210698062
- Cited by
- 168
- References
- 18
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.